BCEL
-1.32%(-0.00)
Open
0.09
Prev Close
0.09
Day High
0.09
Day Low
0.09
Volume
122,115
Avg Volume
267,000
52W High
1.20
52W Low
0.05
Analyst Coverage

No analyst coverage available for this stock.

PRICE
Prev Close
0.09
Open
0.09
Day Range0.09 – 0.09
0.09
0.09
52W Range0.05 – 1.20
0.05
1.20
3% of range
VOLUME & SIZE
Avg Volume
267.0K
FUNDAMENTALS
P/E Ratio
-0.0x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.47
Market-like
TECHNICAL
RSI (14)
49
Bearish momentum

BCEL News

About

atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. with its immune repertoire capture™ (irc™) technology, atreca has an unparalleled insight into how cancer patients’ immune responses can drive better clinical outcomes. atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today’s patients is the key to creating a new generation of therapies. atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health. if you are interested in becoming part of the atreca team, our open positions can be found at: http://www.atreca.com/careers/

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
John Orwin